Seglitide

• UNSPSC Description:

  Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes[1][2][3].

• Target Antigen:

  Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Metabolic Disease; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/seglitide.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H](NC([C@@H](N(C([C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)CC2=CC=CC=C2)=O)C)C)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45

• Molecular Weight:

  808.96

• References & Citations:

  [1]Dimech J, et al. Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria. Br J Pharmacol. 1993;109(4):898-899.|[2]Bhattarai J P, Kaszas A, Park S A, et al. Somatostatin inhibition of gonadotropin-releasing hormone neurons in female and male mice[J]. Endocrinology, 2010, 151(7): 3258-3266.|[3]Hartmann J, et al. Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678. Life Sci. 1989;45(3):267-74.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  81377-02-8